Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Avacc 3 has significant advantages over existing whooping cough vaccines
All the capex is being met through internal accruals only
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Subscribe To Our Newsletter & Stay Updated
